Drugs in ATC Class M01AG

Up to Top Level ATC Classes

Up to M - Musculo-skeletal system

Up to M01 - ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS

Up to M01A - ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS

Drugs in ATC Class: M01AG - Fenamates

Tradename	Generic Name
MEFENAMIC ACID	mefenamic acid
PONSTEL	mefenamic acid

ATC Class M01AG Fenamates: Market Dynamics and Patent Landscape for Diclofenac-Free NSAID Alternatives

Last updated: June 13, 2026

Fenamates are a niche segment within ATC M01AG, dominated commercially by mefenamic acid and related products in several markets. Patent protection across the class is largely expired or near-expiry for core APIs, while remaining leverage sits in formulation, dosing-regimen, crystalline form, and method-of-use patents in selected jurisdictions. For new entrants, the near-term IP barrier is usually not the active ingredient but end-to-end product development coverage and Orange Book style regulatory listings where applicable.

What patents protect fenamates (ATC M01AG) like mefenamic acid and meclofenamic acid?

Which active ingredients define the M01AG fenamate category

ATC M01AG is the “fenamates” subgroup within topical and systemic NSAIDs (ATC M01A). The subgroup commonly maps to:

• Mefenamic acid (anthranilic acid derivative NSAID; oral and some country-specific dosage forms)
• Meclofenamic acid (anthranilic acid derivative NSAID; oral)
• Other fenamate-related NSAIDs that appear in national formularies depending on country mapping and classification practice

Because fenamates are long-established generics in many geographies, the patent landscape typically shifts from API patents to secondary patents (formulation, polymorph/crystal, salts/co-crystals, dosing regimen, and manufacturing processes).

Patent estate typical for fenamates: where exclusivity usually comes from

Across fenamates portfolios in major patenting countries, remaining patentable subject matter tends to fall into four buckets:

1. Formulation patents

   • controlled-release or delayed-release matrices
   • gastro-resistant tablets/capsules
   • taste-masked suspensions
   • fixed-dose combinations (FDC) with antacids or other analgesics in some jurisdictions

2. Solid-state patents

   • specific polymorphs or crystal forms
   • defined particle size distributions for uniform dissolution
   • hydrate/solvate forms and drying/manufacturing controls

3. Method-of-use patents

   • treatment of specific indications, subpopulations, or dosing schedules (example: migraine-like pain analogs, dysmenorrhea subtypes, or post-operative analgesia constructs)
   • sometimes anchored to clinician-defined regimens rather than new compounds

4. Manufacturing and process patents

   • improved synthesis routes for impurity control
   • alternative crystallization steps that improve yield or stability

How many patents cover fenamates?

For fenamates as a category, the number of “live” patents is not stable because it depends on country-by-country secondary filings and filing strategies by originators and later line-extension holders. Practically:

• API patents are almost always expired
• live patents (when present) are usually dozens across a multi-jurisdiction portfolio for a specific branded product’s line-extensions, but single digits to low double digits in a target jurisdiction for any one marketed strength/form

Jurisdiction pattern that matters for licensing and litigation

Business risk typically concentrates in:

• US: where FDA listing and Paragraph IV challenges can matter for oral solids; fenamate generics are frequently on-market, so remaining leverage is tied to any current listed patents for a specific NDA/ANDA product.
• EU (EMA routes): fewer Orange-Book style filings but national SPC and local patent enforcement are important.
• UK, Canada, Australia, Japan: local validity/enforcement and whether line extensions were filed.

When does fenamate exclusivity end and when can generics enter?

What timeline usually governs first generic entry

Fenamates have long histories of use. The exclusivity timeline for the API is generally decades behind current day. The practical generics timeline is therefore driven by:

• expiration of the last relevant secondary formulation or method-of-use patent
• whether a product is still listed for patent-protected patents in US FDA systems (analogous exclusivity and patent listing constructs)
• local regulatory approval pathways and any country-specific data exclusivities

Key functional question for investors

“How soon can a generic (or another NDA/ANDA applicant) launch without infringement?” For fenamates, the answer is almost always:

• if no current listed/active patents cover the specific strength and dosage form, generic entry risk is lower
• if a line-extension exists (e.g., extended-release), then design-around becomes the bottleneck

Exclusivity still relevant in practice: what to check

Even when API patents are expired, remaining exclusivity risk exists for:

• specific dosage forms (IR vs ER)
• specific crystalline form claims
• specific dissolution/particle size parameters in claims
• specific patient-treatment protocols if method-of-use claims are asserted

What is the Orange Book status for fenamates like mefenamic acid?

No single “Orange Book status” applies to ATC M01AG as a whole because Orange Book listings are product and applicant specific. The relevant commercial question is product-level: which US ANDA/NDA products for mefenamic acid or meclofenamic acid are listed with any active patents, and what claim types they cover (composition, formulation, use, manufacturing).

From an enforcement and investment standpoint, the operational checklist for fenamates is:

• identify the exact FDA application(s) covering the intended strength + dosage form
• map which patents are listed for that product
• track which listed patents are the “blocking” ones (device-like or formulation-specific claims that are hard to design around)

How strong is the patent estate for mefenamic acid and meclofenamic acid in major markets?

Strength profile: what tends to be enforceable

Fenamate secondary patents can be enforceable if the claims are specific and supported by solid-state and formulation characterization. Strength commonly clusters around:

• defined polymorph/crystal claims
• defined process parameters in manufacturing (if supported by examples and data)
• defined dissolution profile targets
• defined combination ratios in FDC claims

Weakness profile: what tends to be litigated or narrowed

Fenamate line-extension patents can face validity pressure when:

• claims are broad around excipients without tight structural/compositional limits
• polymorph claims overlap with known forms already disclosed in the literature
• process claims are functionally defined without clear, reproducible boundaries

Design-around likelihood

Design-around is usually feasible when the remaining patents are:

• formulation-specific but allow multiple dissolution-matching alternatives
• crystalline-form dependent but multiple polymorphs are non-infringing and accessible by standard screening
• method-of-use dependent but narrow to a specific dosing schedule that a competitor can avoid

Which companies are challenging fenamate patents via Paragraph IV?

ATC M01AG is broad, and Paragraph IV activity is product- and jurisdiction-specific. For a reliable competitor map, the analysis must tie to:

• the exact US listed patents
• the ANDA filers linked to any Paragraph IV notice
• any settlement agreements that include “carve-outs” by dosage form

A general “who is challenging fenamates” answer risks being wrong at business decision level because Paragraph IV filings frequently target a single listed patent for a single NDA/ANDA product. Without product-specific Orange Book mapping and litigation docket details, a defensible “challenger list” cannot be produced.

What formulations are protected by fenamate patents?

Formulation claim targets that drive freedom-to-operate (FTO)

For fenamates, protected formulations most often target:

• extended-release matrices
• controlled water uptake and drug release through polymer blends
• gastro-resistant layers
• specific excipient systems with quantified dissolution outcomes
• particle size specifications and manufacturing milling ranges

Design-around pathways used by generic manufacturers

Common design-around strategies:

• switch to IR vs ER dosage form
• modify polymer type or ratio while meeting dissolution specs
• use a different solid-state form if the patent covers only one polymorph/hydrate/solvate
• adjust granulation and compression parameters that move impurity profiles

What patent litigation affects fenamates and their generics?

Litigation risk again needs product-specific linking to:

• US federal court cases (e.g., Hatch-Waxman infringement actions)
• UK Patents Court actions
• EP or national validity/enforcement for formulation/crystal/process patents

Without named cases and docket mapping to a specific mefenamic acid or meclofenamic acid product, an actionable litigation landscape cannot be stated.

What generic entry risks exist for fenamates in the US and EU?

Primary risk drivers

1. Remaining listed patents for a specific product form
2. Infringement risk via solid-state and dissolution similarity
3. Injunction leverage if a competitor launches during active litigation
4. Regulatory labeling constraints if method-of-use or dosing claims are tied to labeling

Where generic risk is usually low

• when only old API patents exist and are long expired
• when the last remaining patents are method-of-use but labeling does not match the protected protocol
• when competitors can switch to non-infringing salts, forms, or release profiles

Where generic risk is usually high

• extended-release or gastro-resistant formulations with narrow claim scope that is hard to reproduce without matching dissolution
• crystal/polymorph claims with no easy alternative form that avoids infringement
• combination products if the patented ratio is tightly claimed

How do fenamates compare with other NSAID classes in patent and market dynamics?

Fenamates face a different competitive structure than:

• COX-2 selective inhibitors (more complex patent estates historically)
• diclofenac derivatives and topical NSAIDs (often have stronger formulation-specific patent coverage)
• ibuprofen/naproxen legacy generics (very mature; patent leverage mostly gone)

Compared with those classes, fenamates typically show:

• higher likelihood of broad generic availability
• smaller number of viable line-extension products per country
• a patent strategy that favors local formulation differentiation rather than new molecular entities

Key Takeaways

• The M01AG fenamate category is primarily composed of established anthranilic acid NSAIDs such as mefenamic acid and meclofenamic acid.
• In most major markets, API exclusivity is largely expired; current patent leverage is typically in secondary patents covering formulation, solid-state forms, manufacturing, or specific dosing/indications.
• Generic entry risk is driven by product-specific remaining protections, not the class-level API history.
• For FTO, the critical path is mapping: active FDA-labeled product → listed patents (if US) → claim types (composition/form/use) → design-around feasibility.
• Litigation and Paragraph IV activity can exist but must be assessed at application and patent granularity, not at the ATC class level.

FAQs

1. Which patent claim types most commonly remain active for mefenamic acid products?
   Formulation (release profile/excipients), solid-state (polymorph/crystal form), and process parameters are most common in practice when API patents have expired.

2. Does switching from immediate-release to extended-release generally avoid fenamate formulation infringement?
   Often it changes claim coverage materially, but it depends on whether patents claim broadly around dissolution targets rather than only specific release formats.

3. Can a generic launch for fenamates if only method-of-use patents are listed?
   If labeling and actual marketed use avoid the protected regimen and claim scope, risk can be reduced, but it depends on how tightly method-of-use claims are drafted.

4. What solid-state changes are most relevant for fenamate patent design-around?
   Polymorph/hydrate/solvate selection, particle size, and dissolution-linked parameters are the highest-leverage design-around variables.

5. Why can two mefenamic acid generic products still have different IP risk?
   Different dosage forms, strengths, manufacturing processes, and solid-state forms can map to different claim sets even when the API is the same.

References

1. WHO Collaborating Centre for Drug Statistics Methodology. ATC classification system.
2. FDA. Drugs@FDA (application and product labeling database).
3. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.